共 50 条
Effectiveness and Safety of Herbal Medicine for Atopic Dermatitis: An Overview of Systematic Reviews
被引:10
|作者:
Kwon, Chan-Young
[1
]
Lee, Boram
[2
]
Kim, Suran
[3
]
Lee, Jaesuk
[3
]
Park, Minjung
[3
]
Kim, Namkwen
[3
,4
]
机构:
[1] Dong Eui Univ, Coll Korean Med, Dept Oriental Neuropsychiat, 62 Yangjeong Ro, Busan 47227, South Korea
[2] Korea Inst Oriental Med, Clin Med Div, 1672 Yuseongdae Ro, Daejeon 34054, South Korea
[3] Natl Inst Korean Med Dev, Guideline Ctr Korean Med, 173 Toegye Ro, Seoul 04554, South Korea
[4] Pusan Natl Univ, Dept Ophthalmol & Otolaryngol & Dermatol, Sch Korean Med, 20 Geumo Ro, Yangsan Si 50612, Gyeongsangnam D, South Korea
关键词:
ECZEMA;
COMPLEMENTARY;
GUIDELINES;
MODELS;
D O I:
10.1155/2020/4140692
中图分类号:
R [医药、卫生];
学科分类号:
10 ;
摘要:
Objectives. Herbal medicine (HM) is attracting attention for treating atopic dermatitis (AD). This overview was conducted to summarize and critically evaluate the current systematic reviews (SRs) on HM for the treatment of AD.Methods. Through comprehensive searches, all relevant SRs on HM for AD published until May 2020 were included. The quality of included SRs was assessed using the AMSTAR-2 tool. Moreover, original randomized controlled trials (RCTs) included in the SRs were resynthesized to investigate the efficacy and safety of oral HM for AD. The quality of evidence for the main findings was evaluated using the GRADE approach.Results. Nine SRs were included in this overview. HM showed significantly better efficacy in terms of total effective rate (TER), itching and sleep symptom scores, quality of life, and the dose of topical treatment used compared with placebo. HM as a monotherapy and/or an adjunctive therapy to conventional medication (CM) showed significantly better results on the efficacy, symptom relief, and some laboratory parameters related to the inflammatory response. The methodological quality was generally low. When 58 original RCTs were reanalyzed, HM showed significantly lower SCORing Atopic Dermatitis (SCORAD) score and higher TER than the placebo or CM. In terms of the safety profile, HM was not significantly different from the placebo and was better than CM. The quality of evidence ranged from "moderate" to "very low."Conclusion. The results suggested that HM as a monotherapy or an adjunctive therapy is promising for the treatment of AD. However, due to low methodological quality and low quality of evidence, further rigorous, well-designed, high-quality SRs, and RCTs are needed to make clinical recommendations on HM use.
引用
收藏
页数:15
相关论文